Evaluation of cancer therapy with iPS-ML aiming at clinical development

2016 Fiscal Year Final Research Report

• Project/Area Number: 26290057
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Partial Multi-year Fund
• Section: 一般
• Research Field: Tumor therapeutics
• Research Institution: Kumamoto University
• Principal Investigator: SENJU Satoru 熊本大学, 大学院生命科学研究部(医), 准教授 (50274709)
• Co-Investigator(Kenkyū-buntansha): 植村 靖史 国立研究開発法人国立がん研究センター, その他部局等, その他 (40364781)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: がん治療 / 免疫療法 / 細胞治療 / iPS細胞 / 肝臓がん / インターフェロン

Outline of Final Research Achievements

We hypothesized that macrophages producing IFN-beta may be useful for anti-cancer therapy. However, it is impossible to amplify human peripheral blood monocytes and thus the quantity of macrophages generated by donated blood may be insufficient for clinical use. We established a method to induce proliferation of human iPS-cell derived myeloid cells (iPS-MC) by introduction of genes promoting cell proliferation to generate iPS-cell derived myeloid/macrophage cell line (iPS-ML).
When iPS-ML were injected into the mice with pre-established peritoneal tumors (xenograft model of peritoneally disseminated cancer), iPS-ML infiltrated into the tumor tissues. In xenograft models, iPS-ML introduced with an expression vector for IFN-beta (iPS-ML/IFN-beta) profoundly inhibited the growth of peritoneally disseminated human gastric and pancreatic cancer. In addition, therapy with iPS-ML/IFN-beta was effective in xenograft models of primary and metastatic liver cancer.

Free Research Field

免疫学